Solventum Corp

Note 17 to the condensed consolidated financial statements provides an overview of Solventum’s business segments in addition to disclosures relating to Solventum’s segments. We manage our operations in four business segments. Our reportable segments are MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. Our Chief Operating Decision Maker evaluates segment operating performance using net sales and business segment operating income.

Corporate and Unallocated

Certain items are maintained at the corporate level and not allocated to the segments (“Corporate and Unallocated”). Corporate and Unallocated includes amortization of acquired intangible assets, restructuring and related charges, and benefits or costs related to capitalized manufacturing variances. In addition, Corporate and Unallocated includes Spin-Off and separation related costs. Spin-Off and separation related costs include any costs incurred as part of our separation from 3M and costs to setup operations as a standalone company, including system implementations, manufacturing relocations, legal entity separations, certain equity awards granted as part of the Spin-Off, profit mark-ups on transition service arrangements with 3M and other one-time costs.

Corporate and Unallocated also includes sales and cost of sales related to our supply agreements with 3M and other supply agreements assumed by the Company at Spin-Off related to legacy 3M businesses. Because Corporate and Unallocated includes a variety of miscellaneous items, it is subject to fluctuation on a quarterly and annual basis.

Operating Business Segments

Information related to the Company’s segments is presented in the tables that follow with additional context in the corresponding narrative below the tables.

MedSurg (56.4% and 56.1% of consolidated sales for the three and six months ended June 30, 2025)

Sales in MedSurg were up 4.8%:

•Organic growth was driven by strong broad-based volumes in Infection Prevention and Surgical Solutions, led by surgical solutions and I.V. site management products. Growth benefited from advanced order timing as part of enterprise resource planning and distribution cutovers that were completed during the second quarter 2025.

•Foreign currency translation positively impacted sales by 0.9%.

Business segment operating income margin decreased when compared to the same period last year. The decrease was primarily driven by the impact of higher tariffs on product manufactured during the second quarter of 2025.

Sales in MedSurg were up 4.1%:

•Organic growth was led by Infection Prevention and Surgical Solutions, led by I.V. site management and hospital consumable products.

•Foreign currency translation negatively impacted sales by (0.3%).

Business segment operating income margin decreased when compared to the same period last year. The decrease was driven by higher costs to stand-up and operate our standalone structure after Spin-Off.

Dental Solutions (15.6% and 15.8% of consolidated sales for the three and six months ended June 30, 2025)

Sales in Dental Solutions were up 2.3%:

•Organic growth in new restorative and prevention solution products was partially offset by a decline in traditional orthodontic products.

•Foreign currency translation positively impacted sales by 1.6%.

Business segment operating income margin increased when compared to the same period last year primarily due to lower business operating expenses.

Sales in Dental Solutions were up slightly at 0.1%:

•Organic growth in new restorative and prevention solutions products was partially offset by a decline in traditional orthodontic products.

•Foreign currency translation negatively impacted sales by (0.2%)

Business segment operating income margin decreased when compared to the same period last year as a result of higher costs to stand-up and operate our standalone structure after Spin-Off.

Health Information Systems (15.7% and 15.8% of consolidated sales for the three and six months ended June 30, 2025)

Sales in Health Information Systems were up 3.4%:

•Organic growth was driven by continued adoption of our Solventum™ 360 Encompass TM.

•Clinician productivity solutions declined primarily due to impacts from changing market conditions.

•Foreign currency translation positively impacted sales by 0.2%.

Business segment operating income margin increased when compared to the same period last year, driven by sales price growth, product mix, partially offset by the impact of higher compensation costs.

Sales in Health Information Systems were up 3.5%:

•Positive organic growth was driven by continued adoption of our Solventum™ 360 Encompass TM and performance management solutions.

•Clinician productivity solutions declined primarily due to impacts from changing market conditions.

Business segment operating income margin increased when compared to the same period last year, driven by sales price growth, product mix, partially offset by the impact of higher compensation costs.

Purification and Filtration (11.7% and 11.7% of consolidated sales for the three and six months ended June 30, 2025)

Sales in Purification and Filtration were up 5.4%:

•Organic growth was driven by growth in both bioprocessing filtration and industrial filtration, which benefited from added production capacity, partially offset by declines in membrane OEM products.

•Foreign currency translation positively impacted sales by 2.3%.

Business segment operating income margin increased due to volume growth, favorable sales mix and a benefit resulting from the Company stopping depreciation on assets classified as held for sale.

Sales in Purification and Filtration were up 2.2%:

•Organic growth was driven by growth in both bioprocessing filtration and industrial filtration, which benefited from added production capacity, partially offset by declines in membrane OEM products.

•Foreign currency translation positively impacted growth by 0.1%.

Business segment operating income margin increased due to volume growth, favorable sales mix and a benefit resulting from the Company stopping depreciation on assets classified as held for sale, partially offset by additional standalone structure costs.